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In recent years, it has become increasingly important to get as much as possible
information on clinical efficacy already in the early phases of drug development. For proof
of concept (POC) studies testing novel anti-inflammatory drugs in asthma, there are
several validated exacerbation models, inducing various aspects of the airway inflamma-
tion and airway responsiveness. The choice of the appropriate asthma model depends on
the drug’s targets within the inflammatory process.
For adequate assessment of the drug’s anti-inflammatory potential, it is crucial to choose
adequate (surrogate) biomarkers. Ideally, these should include measures of airway
response, central and peripheral airway inflammation and airway hyperresponsiveness.
Overall, there are validated non-invasive sampling techniques for the measurement of
inflammatory markers in asthma that can be applied as outcome parameters in early
clinical trials. If adequately implemented, these measurements can provide early
indication of proof of pharmacological and potential therapeutic efficacy—even in first
administration to humans.
& 2007 Elsevier Ltd. All rights reserved.Contents
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Traditionally, there are four phases (I–IV) in the clinical drug
development. While the early-phase studies mainly focus on
human pharmacology, the drug’s efficacy becomes more and
more important in the later phases. In recent years, it has
become increasingly important to get as much as possible
information about the ‘proof of mechanism’ as early as
possible in drug development.
Asthma is a chronic airway disease, characterized by
variable airway obstruction, airway inflammation, airway
hyperresponsiveness (AHR) and remodeling.1,2 These fea-
tures are interrelated (Figure 1). Typically, the airway
inflammation is a T-helper-2 (TH2) cells-driven process with
activated eosinophils as main effector cells. Once activated,
these cells release bronchoactive and pro-inflammatory
mediators, perpetuating the inflammatory airway process
and inducing AHR. Obviously, these events are not present in
non-atopic, healthy subjects. Hence, in early clinical drug
development testing the proof of mechanism (POM) of novel
anti-asthma therapy, it is mandatory to move into asth-
matics as soon as possible. Proof of concept (POC) usually
relates to the situation when one or more proved mechan-
isms relate to an expected clinical effect.
Traditionally, in POC studies testing a drug’s anti-
inflammatory (‘controller’) potential, the changes in symp-
tom scores and lung function have been used as measures for
a drug’s clinical efficacy. However, according to concurrent
evidence, symptoms and lung function have been shown to
be poorly related with the underlying airway inflammation
and AHR and should per se only be used to evaluate a drug’s
bronchodilator properties.3–5 In addition, in asthmatic
patients dissociation between airway inflammation and
AHR has been reported.6 Hence, drug’s clinical efficacy
should preferably be assessed on a combination of outcomeFigure 1 Schematic relationship among asthma characteristics.parameters, including airway responses, (surrogate) bio-
markers of airway inflammation and AHR.
In this short review, we aim to provide a practical
overview of the most important clinical exacerbation
models of asthma along with their main underlying
mechanisms, strengths and limitations. In addition, we
shortly discuss the added value of (validated) sampling
methods and biomarkers to early clinical trials in asthma
testing anti-inflammatory therapy.Modeling features of asthma for clinical proof
of concept (POC) studies
Modeling the asthmatic airway inflammation:
exacerbation models
Already in early POC studies of asthma, it is essential to
demonstrate a drug’s anti-inflammatory and/or disease-
modifying properties. However, studies in patients are
logistically and economically hampered and will usually
require large numbers of participants during long-term
observations.5 In contrast, validated exacerbation models
of asthma are useful tools for POC studies, requiring short-
term pretreatment in (relatively) small numbers of pa-
tients.5,7 There are several validated bronchial challenges
that can induce or mimic exacerbations of asthma in humans
in vivo. The principle of these models is based on
administration of a relevant stimulus that can induce an
acute inflammatory airway response in susceptible sub-
jects.8 Depending on the mechanism of action, these stimuli
can trigger more or less specific inflammatory pathways, and
subsequently ‘mimic’ several immunological and pathophy-
siological aspects of asthma (Table 1).7–15 For a POC study
with a novel drug, it is crucial to choose a relevant
exacerbation model that should include the targets for the
drug’s mechanism of action. In this mini-review, we will
provide a short overview of the most important exacerba-
tion models of asthma, based on the most important
environmental physiological stimuli, including exercise or
cold, dry air challenge, pharmacological stimuli (e.g. LPS,
aspirin), air pollutants (e.g. ozone), respiratory viruses
(rhinovirus) and allergens.7–15Exercise and related challenges
Although the mechanism underlying bronchoconstriction in
exercise challenge is not fully understood, airway cooling
and drying are thought to induce the release of bronchoac-
tive mediators (mainly histamine, prostaglandin D2 and
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Table 1 Human exacerbation models of asthma
Stimulus Immunological mechanism Drawbacks
Exercise, cold dry air,
mannitol
Mast cells+mediators  Limited model
 Requires specialized equipment
 Not suitable for elderly/handicapped
Endotoxin (LPS) Neutrophils+mediators  Time-consuming
 Requires close monitoring of airway and systemic effects
(safety)
Ozone Neutrophils+mediators  No standardization
 Requires specialized equipment
 Time-consuming
 (Mild) haemoptysis
Virus Eosinophils+neutrophils+mediators  Difficult recruitment (RV16-negative subjects)
 Requires additional safety procedures due to viral
inoculation/contamination
Aspirin Eosinophils+mediators  Strenuous, time-consuming procedure
 Requires close monitoring (safety)
Allergen Mast cells+eosinophils+mediators  Strenuous, time-consuming procedure
 Requires close monitoring (safety)
Steroid tapering Eosinophils+mediators  Lengthy trials
 Intensive monitoring
Exacerbation of ICS-sensitive components of airway inflammation.
Z. Diamant et al.334cysteinyl leukotrienes) from mast cells possibly by osmotic
stimulation of the respiratory epithelium.8,16,17 In addition,
sensory nerves within the airways seem to contribute to the
complex pathophysiology of exercise-induced bronchocon-
striction.16 Hence, exercise and related ‘mast cell-driven’
bronchoprovocation tests including isocapnic hyperventila-
tion of cold, dry air and mannitol challenge are limited
models of asthma enabling to test the efficacy of therapy
directed against mainly mast-cell derived and sensory
nerves-mediated mechanisms.8,16,18LPS-induced airway inflammation
Inhaled Escherichia coli-derived lipopolysaccharide (LPS) is
a reproducible model of airway neutrophilia inducing
bronchoconstriction and AHR in susceptible healthy and
asthmatic subjects.19,20 In asthma, a close genetic link has
been shown between LPS, induction of hyperresponsiveness
and functional Toll like receptor 4 (a transmembrane
receptor for LPS).21 In addition to its potent proinflamma-
tory properties within the airways, inhaled LPS causes dose-
related systemic effects including fever, reduced blood
pressure, and constitutional symptoms that are not asso-ciated with the airway responses.9 Despite these character-
istics requiring prolonged clinical observation, the LPS
model has been successfully applied in intervention studies
of asthma.22
Ozone challenge
Ozone has also been shown to induce airway neutrophilia and
AHR both in healthy responders and asthmatic subjects.10,23
Although specific equipment is required and some investigators
have encountered mild hemophtysis following ozone chal-
lenge, this model seems a useful tool in evaluating drugs
targeting neutrophilic airway inflammation.10
Rhinovirus-induced exacerbations
Respiratory viruses, and especially the rhinoviruses (RVs),
are amongst the major triggers of asthma exacerbations.
Although still incompletely understood, the pathophysiology
of respiratory viruses in both healthy and asthmatic subjects
has attracted many research groups. Viruses can replicate
within the airway epithelial cells, induce both local and
systemic release of pro-inflammatory mediators and cause
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subjects, viral infections are associated with an enhanced
TH-2 response resulting in recruitment of eosinophils into
the airways, with a longer-lasting airway eosinophilia in the
asthmatics.24,25 In addition, increased numbers of airway
neutrophils have been encountered during the acute
exacerbation phase.24 Furthermore, the pathophysiology of
respiratory virus infections has been associated with
aberrant neural control of the airways causing virus-induced
AHR.24
Since virus-induced asthma exacerbations only poorly
respond to inhaled corticosteroids, more insight into the
pathophysiology of viral respiratory tract infections is
needed to provide rationale for new therapeutic ap-
proaches. In this respect, experimental RV infections may
be a suitable tool. Previous studies in asthmatics showed
that experimental RV infections are capable of inducing
features of exacerbation, including symptoms, AHR and
sputum eosinophilia.11 Although this exacerbation model
requires experienced medical staff and specific safety
precautions, it may be helpful in intervention studies
targeting both the direct and the indirect sequelae of the
virus-induced asthma exacerbations.
Aspirin challenge
Aspirin challenge is a specific and sensitive tool for both
diagnostic and research purposes in patients with aspirin-
intolerant asthma (AIA). This challenge can be performed
either with oral aspirin (ASA) or inhaled (or nasal) solutions
of lysine-aspirin (L-ASA).12 In sensitized patients, aspirin
challenge will provoke an acute bronchoconstrictor re-
sponse, often accompanied by extra-bronchial symptoms
(conjunctivitis, rhinorrhoea, nasal congestion, gastro-intest-
inal symptoms, flushing of head and neck). The aspirin-
induced inflammatory response is characterized by profound
airway eosinophilia releasing large amounts of cysteinyl
leukotrienes that can be quantified by urinary leukotriene
E4.
12,26 Although a time-consuming procedure requiring
close monitoring for potential anaphylaxis, aspirin challenge
has been shown to be a useful tool for intervention studies
with drugs targeting the aspirin-induced airway responses,
e.g. anti-leukotriene therapy.27
Allergen challenge
Allergy is a key mechanism leading to both the development
and persistence of airway inflammation and structural
changes within the airways that may result in symptomatic
asthma.28 Hence, a large number of novel treatment
modalities are presently being developed targeting the
allergic mechanisms within the airways. Methods and tools
that can rapidly predict if a new drug will be effective in
treating this condition are very important in the develop-
ment of new drug entities.
For POC in asthma, there are two allergen challenge
techniques. Segmental allergen challenge is an invasive
method, allowing direct sampling (biopsy, bronchoalveolar
lavage) of a limited part of the airways following locally
instilled allergen.29 Alternatively, inhaled allergen challenge
(and especially when a late asthmatic response (LAR) can beinduced) is a reproducible exacerbation model mimicking
several acute and some chronic features of (allergic)
asthma.13,30 Following inhalation of a relevant allergen, an
early asthmatic response (EAR; i.e. a self-limiting, mainly
IgE-mast cell- triggered phenomenon) occurs in sensitized
asthmatics within 10–30min, followed by a LAR in approxi-
mately 50% of the subjects, mostly occurring within 3–7 h
post-allergen. The LAR is characterized by a more persistent
airway inflammation in which activated eosinophils and
their products induce AHR and structural airway changes
(remodeling).13,31
Especially when combined with non-invasive sampling
techniques enabling to study several aspects of the allergen-
induced airway responses (EAR, LAR and AHR) and their
relation to inflammatory events within the airways, the
allergen challenge is a useful tool in POC studies with novel
drugs targeting allergen-induced mechanisms.13,31,32 And if
properly conducted, allergen challenge can predict a drug’s
clinical efficacy.7,13 Indeed, agents inhibiting the sequelae
of the LAR have generally shown efficacy in clinical asthma,
while those that did not affect the LAR have not. Based on
previous studies and although not all drugs that did not show
efficacy against the LAR have been tested in a clinical
setting, this model seems to have a moderate positive
predictive value, but an excellent negative predictive
value.13Steroid tapering
Controlled tapering off inhaled corticosteroids is another
exacerbation model that can be used in clinical trials of
asthma.14 Depending on the severity of asthma, the initial
corticosteroid dose and the speed of the dose tapered,
asthma exacerbation can be induced within days or weeks,
characterized by bronchoconstriction, increased AHR ac-
companied by sputum and blood eosinophilia.14,15 This
model can be implemented in intervention studies of asthma
with novel and existing drugs. The drawbacks of corticos-
teroid tapering obviously concern the lengthy and intensive
trials, requiring a run-in period to obtain clinical stability
(2–4 weeks) and usually an additional 4–5 weeks of tapering
with close monitoring for potential early drop-outs due to
severe exacerbations.15Indices of airway hyperresponsiveness
AHR is a consistent characteristic of asthma. In the past
decade, circumstantial evidence has been provided that
AHR is composed of two semi-independent components: a
persistent and a variable component.33 The persistent or
‘fixed’ AHR is best reflected by direct stimuli (with direct
action on airway smooth muscle cells) and is likely to be
related to structural changes within the airway wall, i.e.
airway remodeling.16,33 This AHR component is relatively
refractory to treatment with inhaled corticosteroids. The
variable or ‘inducible’ AHR is reflected by indirect stimuli
(mediated by inflammatory cells and sensory nerves). This
AHR component is associated with airway inflammation,
responds well to anti-inflammatory treatment with ICS, and
thus reflects asthma activity.16,34
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Stimuli inducing AHR can be divided into direct and indirect.
The direct stimuli (exemplified by cholinergic agents such as
methacholine) interact directly with receptors on airway
smooth muscle cells and subsequently cause airway narrow-
ing. These validated bronchial challenge tests are generally
used for both diagnostic and research purposes.8,33 Alter-
natively, indirect stimuli cause bronchoconstriction through
intermediate pathways inducing the release of endogenous
mediators from inflammatory cells (mast cells and others)
and sensory nerves (Figure 2).16 Similarly to direct chal-
lenges, indirect bronchial challenges are mostly standar-
dized procedures with physical (exercise, hyperventilation,
cold dry air, non-isotonic aerosols) or pharmacological
(histamine, mannitol, adenosine monophosphate (AMP))
stimuli.8,33 An ERS Task Force document has been written
reviewing the pathophysiology, methodology and recom-
mendations of most of the indirect challenges.16 Most
indirect challenges appear to act through similar mechan-
isms (inflammatory mediators and neurotransmitters).16,33
Intervention studies with inhaled corticosteroids verify that
changes in airway responsiveness to indirect stimuli such as
exercise, AMP or mannitol provide more information on
airway inflammatory control than symptoms and lung
function or airway reactivity to direct stimuli.34,35 From
the logistic point of view, there are marked differences in
the costs and equipment needed for indirect challenges. In
this respect, bronchial challenge with dry powder mannitol
has been shown to possess superior properties: this very
simple method, consisting of an inhaler and capsules, has
been shown to be a highly reproducible test for the diagnosis
of asthma (sensitivity: 89% and specificity: 95%, respec-
tively).36
In conclusion, indirect challenges appear sensitive mea-
sures of a drug’s anti-inflammatory potential and theFigure 2 Mechanisms underlying indirectassociated clinical outcome (asthma control) and hence,
may be useful tools in POC studies and for clinical practice
(diagnosis and treatment monitoring).16,36 However, since
especially indirect challenges have been shown to induce
some degree of airway inflammation (and tachyphylaxis),
when applied in clinical trials, a washout of at least 48 h is
needed between consecutive challenges/tests.8,16Non-invasive inflammometry
In contrast with the classical paradigm, symptoms and lung
function are poorly correlated with the underlying airway
inflammation or AHR.1,5,37,38 In view of this dissociation, the
efficacy of novel drugs should be evaluated by multiple
(surrogate) biomarkers instead of lung function measure-
ments only.6 In the past decade, several more or less non-
invasive methods have been developed for sampling or
assessment of the airway inflammation in asthma.7 Exhaled
nitric oxide (eNO) and hypertonic saline-induced sputum are
validated methods, increasingly applied both in clinical
practice and clinical trials.39,40 Exhaled breath condensate
(EBC) is another, relatively novel, non-invasive technology,
allowing collection and measurement of various volatile
substances potentially implicated in disease processes—
many of these markers still await validation.41,42 Overall,
these sampling methods provided important information on
the pathophysiology and immuno-kinetics of asthma and
yielded valuable markers of disease activity/severity and
phenotyping. Recently, Task Force documents and recom-
mendations have been issued on the currently applied non-
invasive sampling techniques in asthma (‘inflammome-
try’).39–41 As a result, several (surrogate) biomarkers have
now been validated as markers of disease activity/severity
which makes them suitable tools for both clinical monitoring
(eNO and sputum eosinophils have been shown to correlateand direct airway hyperresponsiveness.
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bations) and as efficacy biomarkers for POC studies in
asthma.7,31,37,38,43 If adequately powered and taking into
account potential carry-over-effects of consecutive chal-
lenge tests,8,16 measurements of airway inflammation and
AHR can be implemented into the exacerbation models.5,7,31
In addition, still novel and more sensitive detection
techniques are being explored and developed, such as
measurements of molecular components in exhaled air
(proteonomics, metabolomics), reflecting different aspects
of the airways inflammation.44,45 Future validation studies
are needed to evaluate their suitability for clinical
monitoring and early drug development.
Another dimension of asthmatic inflammation is the
concept of asthma as a systemic small airways disease.
According to this concept, small airways inflammation is
closely associated with clinical entities such as nocturnal
asthma, exercise-induced bronchoconstriction and asthma
exacerbations.46 While induced sputum mainly reflects
inflammation of the central airways, bronchoalveolar lavage
(BAL) may better reflect inflammatory events in the
peripheral airways.47 Theoretically, EBC could be a better,
non-invasive tool for small airways monitoring, although this
has to be established in clinical trials. Fractional NO
measurement is another instrument for monitoring of the
inflammation within peripheral airways. Using this method
in corticosteroid refractory asthmatics, a clear suppression
of the inflammatory response was shown in the central
airways, measured as bronchial flux, whereas the peripheral
NI (alveolar NO) remained unchanged.48
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